Valeant Pharmaceuticals International Inc

Valeant Pharmaceuticals International — CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference 2006

50 slides from Valeant Pharmaceuticals International's conference presentation, Apr 5, 2006

  1. Slide 1: CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference

    Slide 1: CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference

    CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference April 5, 2006

  2. Slide 2: Forward-Looking Statement

    Slide 2: Forward-Looking Statement

    VALEANT Pharmaceuticals International Forward: cing tatement This presentation co! joking statements, including, but not limited to, statements regarding the anticipated impact of the restructuring program on the : company's operations and expenses, the charge associated with the program, ex nected

  3. Slide 3: Announces Restructuring

    Slide 3: Announces Restructuring

    Announces Restructuring

  4. Slide 4: Strategic Restructuring Steps

    Slide 4: Strategic Restructuring Steps

    Rationalize pre-clinical research Out-license pradefovir and VRX-840773 Reduce commercial regions to three - re-align operations Reduce Selling to 29-31% of sales in 2006 Reduce G&A to 11-13% of sales in 2006 Reduce manufacturing facilities further Reduce COGS to ensure 20-25% by 2008 Reduce headcou

  5. Slide 5: Strategic Restructuring Benefits

    Slide 5: Strategic Restructuring Benefits

    Accelerate operating improvement plan Increase near-term adjusted earnings Maintain long-term growth Adjusted earnings per diluted share: 2006: > $0.50 2007: > $1.00 2008: > $1.90 (without Viramidine or retigabine) Restructuring charge in 2006 ~ $80 - $100 million Strategic Restructuring Benefits

  6. Slide 6: A unique, global, science-based specialty pharmaceutical company

    Slide 6: A unique, global, science-based specialty pharmaceutical company

    (NYSE:VRX) in the areas of neurology, infectious disease and dermatology A unique, GLOBAL, science-based, specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products

  7. Slide 7: Company Profile

    Slide 7: Company Profile

    Company Profile $ 823 Million in Revenues 400 Products 2,350 SKUs 1,000 Sales Representatives Global Development ai 3,800* Employees Wy VALEANT

  8. Slide 8: Strategic Focus

    Slide 8: Strategic Focus

    Three Regions Ten Markets 20-25 Growth Products Three Development Products Strategic Focus

  9. Slide 9: Growth Strategy

    Slide 9: Growth Strategy

    Growth Strategy R e v e n u e G o a l 2004 2005 2006 2007 2003 2008 Completed BD Ribavirin Royalties Base Business Future Growth* *Pipeline and Business Development

  10. Slide 10: Growth Strategy

    Slide 10: Growth Strategy

    Growth Strategy 2004 2005 2006

  11. Slide 11: Growth Strategy

    Slide 11: Growth Strategy

    Growth Strategy 2004 2005 2006 2007 2003 2008 Non-Promoted Products Promoted Products 44% Growth in Promoted Products in 2005 R e v e n u e G o a l Ribavirin Royalties

  12. Slide 12: Three Therapeutic Areas

    Slide 12: Three Therapeutic Areas

    Three Therapeutic Areas Neurology ds Dermatology

  13. Slide 13: Current Promoted Brands

    Slide 13: Current Promoted Brands

    Solcoseryl Current Promoted Brands

  14. Slide 14: Product Sales by Region 2003

    Slide 14: Product Sales by Region 2003

    AAA North America Latin America Europe East 51 99 136 232 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 North America 19% AAA 10% Latin America 26% Europe 45% Product Sales by Region 2003 Total Product Sales: $518 Million

  15. Slide 15: Product Sales by Region 2005

    Slide 15: Product Sales by Region 2005

    AAA North America Latin America Europe East 9 32 24 35 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 Product Sales by Region 2005 North America 32% AAA 9% Latin America 24% Total Product Sales: $731 Million Europe 35%

  16. Slide 16: Completed Business Development

    Slide 16: Completed Business Development

    Completed Business Development Strategic assets in core therapeutic areas Immediate impact on sales with significant growth potential Infergen TRx growth 84% in 2005 2005 sales of $36.7 million (pre-acquisition) Diastat TRx growth 12% in 2005 2005 sales of $47.6 million

  17. Slide 17: Promoted Products 2005

    Slide 17: Promoted Products 2005

    Promoted Products Non-promoted Products East 55 45 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 Promoted Products - 2005 Promoted Products 55% Total Product Sales: $731 Million Non-promoted products 45%

  18. Slide 18: Top Products 2005

    Slide 18: Top Products 2005

    All Others Top 10 Products East 59 41 Top 10 Products - 2005 All Other Products 59% Total Product Sales: $731 Million Top 10 Products 41%

  19. Slide 19: 2005 R&D Pipeline

    Slide 19: 2005 R&D Pipeline

    2005 R&D Pipeline Discovery Phase 1 Phase 2 Phase 3 Post Approval Pre- Clinical Post Approval: Pending Approval: In Development:

  20. Slide 20: Diastat regulatory and sales update

    Slide 20: Diastat regulatory and sales update

    Purchased from Eli Lilly in 2004 Marketed in Canada 102 percent growth in sales in 2005 88 percent TRx market share Approved in U.S. in 1985 In Discussion with FDA on Updated Label Non-approvable letter on revised label in December 2005 Ongoing discussions with FDA Expect approval of new label in 20

  21. Slide 21: Zelapar Orally Disintegrating Tablets

    Slide 21: Zelapar Orally Disintegrating Tablets

    | NEW | [ Zelapar Eten Orally Disintegrating Tablets

  22. Slide 22: Parkinson's Disease Product Comparisons

    Slide 22: Parkinson's Disease Product Comparisons

    Parkinson's Disease Product Comparisons Medication Mean Reduction in Awake "Off" Time (hrs)* TASMAR (tolcapone)** 3.2 Zelapar (selegiline) 2.2 Mirapex (pramipexole) 2.0 Agilect (rasagiline) 1.4 - 1.8 Permax (pergolide) 1.8 Requip (ropinirole) 1.5 Comtan (entacapone) 1.2 *Hours calculated by subtract

  23. Slide 23: Viramidine (taribavirin)

    Slide 23: Viramidine (taribavirin)

    VIRAMIDINE (taribavirin) O HO HO OH N N N C NH2+ H2N Cl-

  24. Slide 24: VISER1 Summary

    Slide 24: VISER1 Summary

    VISER1 Summary Confirms superior safety profile ITT results disappointing Clear dose response based on weight Higher concentrations of Viramidine do not result in proportional increases in anemia

  25. Slide 25: Viramidine Phase 3 (VISER1) Study Design

    Slide 25: Viramidine Phase 3 (VISER1) Study Design

    Viramidine Phase 3 (VISER1) Study: Design Randomized, Double-blind Multicenter, Parallel-group Study in Treatment-naive Subjects (N = 970) 24 weeks of follow-up 24/48 weeks of treatment* Screening (30 days) Randomization (2:1) Follow-up Ribavirin 1000/1200 mg/QD + PegIntron† Viramidine 600 mg BID +

  26. Slide 26: VISER1 Co-Primary Endpoints

    Slide 26: VISER1 Co-Primary Endpoints

    VISER1 Co-Primary Endpoints Primary safety endpoint: Hemoglobin < 10 g/dL or ^ 2.5 g/dL drop from baseline Superiority test vs. ribavirin Primary efficacy endpoint: Sustained Virologic Response - HCV RNA < 100 copies/mL at FW 24 Non-inferiority test vs. ribavirin

  27. Slide 27: Viramidine Safety: Anemia Incidence

    Slide 27: Viramidine Safety: Anemia Incidence

    Viramidine Safety: Anemia Incidence Hgb <10 g/dL Anytime During Therapy Overall Safety Population Viramidine (FD) Ribavirin (WBD) SVR 0.05 0.24 N = 324 N = 646 P<0.0001 % of Patients

  28. Slide 28: Viramidine Efficacy Analysis

    Slide 28: Viramidine Efficacy Analysis

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.56 0.6 0.53 38% 52% N=646 N=324 (0.072, 0.194) ITT 95% CI for Difference of Proportion

  29. Slide 29: Viramidine Efficacy Analysis

    Slide 29: Viramidine Efficacy Analysis

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 62% 52% N=646 N=421 N=324 N=216 (-0.002, 0.151) 95% CI for Difference of Proportion (0.072, 0.194) ITT PP

  30. Slide 30: Sustained Virologic Response Overall by Region

    Slide 30: Sustained Virologic Response Overall by Region

    95% CI for Difference of Proportion Sustained Virologic Response Overall by Region (PP) NA EU NA/EU ROW Viramidine (FD) 0.54 0.48 0.51 0.56 Ribavirin (WBD) 0.57 0.54 0.55 0.78 54% 57% 48% 55% 55% 78% 56% 51% * Meets non-inferiority criteria N=168 N=100 N=159 N=62 N=327 N=162 N=94 N=54 ? (-0.060, 0.1

  31. Slide 31: Viramidine Efficacy Analysis

    Slide 31: Viramidine Efficacy Analysis

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 51% 56% 62% 52% N=646 N=421 N=324 N=216 N=327 N=162 95% CI for Difference of Proportion (-0.060, 0.118) * (-0.002, 0.151) * Meets non-inferiority criteri

  32. Slide 32: Viramidine Weight Based Analysis

    Slide 32: Viramidine Weight Based Analysis

    Viramidine Weight Based Analysis Overall (PP) Sustained Virologic Response Anemia: <10 g/dL Viramidine mg/kg Viramidine mg/kg <18 19-22 >23 East 0.48 0.64 0.81 47% N=323 66% N=82 81% N=16 <18 19-22 >23 East 0.043 0.024 0.125 2% N=82 4% N=323 12.5% N=16 % of Patients % of Patients

  33. Slide 33: Viramidine Efficacy Analysis

    Slide 33: Viramidine Efficacy Analysis

    Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 51% 56% 62% 52% 62% 60% 42% 53% N=646 N=421 N=324 N=148 N=70 N=92 N=179 N=216 N=327 N=162 (-0.060, 0.118) * (-0.177, 0.079) * (-0.034, 0.213) (-0.002, 0.

  34. Slide 34: Viramidine Next Steps

    Slide 34: Viramidine Next Steps

    Viramidine Next Steps Present VISER1 Data at EASL: April 2006 Complete VISER2: June 2006 Disclose VISER2 Results: 2H06 Discuss Data with outside experts & FDA: 2H06 Economic Assessment: 2H06 Decide regulatory steps for Viramidine: 2H06 Present VISER2 Data at Scientific Forum: TBD

  35. Slide 35: Retigabine

    Slide 35: Retigabine

    RETIGABINE

  36. Slide 36: Retigabine Phase 2: Seizure Rate Reduction

    Slide 36: Retigabine Phase 2: Seizure Rate Reduction

    Retigabine Phase 2 Source: Study 205; Data on file * statistical significance as compared to placebo (p < 0.01) Median Percent Reduction from Baseline in Monthly Total Partial Seizure Rate Placebo + AEDs Retigabine + AEDs Placebo 600 mg/day 900 mg/day 1,200 mg/day East 13 23 29 35 West 30.6 38.6 34.

  37. Slide 37: Retigabine Phase 2: Responder Rate

    Slide 37: Retigabine Phase 2: Responder Rate

    Retigabine Phase 2 Source: Study 205; Data on file * statistical significance as compared to placebo (p < 0.01) Responder Rate (Total Partial Seizures) Placebo 600 mg/day 900 mg/day 1,200 mg/day East 16 23 32 33 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 % Responders (n = 96) (n = 99) (n = 95)

  38. Slide 38: Retigabine Phase 3: 301 Study Design (US)

    Slide 38: Retigabine Phase 3: 301 Study Design (US)

    A randomized, double-blind, placebo-controlled, multicenter, parallel- group phase 3 study to determine the efficacy and safety of retigabine (1200 mg/day) used as adjunctive therapy in refractory epilepsy patients with partial-onset seizures Retigabine Phase 3: 301 Study Design (US) 32 weeks of tre

  39. Slide 39: Retigabine Phase 3: 302 Study Design (ROW)

    Slide 39: Retigabine Phase 3: 302 Study Design (ROW)

    A randomized, double-blind, placebo-controlled, multicenter, parallel- group phase 3 study to determine the efficacy and safety of two doses of retigabine (900 mg/day and 600 mg/day) used as adjunctive therapy in refractory epilepsy patients with partial-onset seizures Retigabine Phase 3: 302 Study

  40. Slide 40: Financial Review

    Slide 40: Financial Review

    Review Financial www.valeant.com

  41. Slide 41: Product Sales

    Slide 41: Product Sales

    Product Sales 2002 2003 2004 2005 Sales 467 518 606 731 Annual *2002 sales reflect wholesale inventory reduction program * ($ In millions)

  42. Slide 42: Same Store Sales

    Slide 42: Same Store Sales

    Same Store Sales 2002 2003 2004 2005 Sales 467 518 586 658 Acquisitions 20 73 Annual *2002 sales reflect wholesale inventory reduction program * ($ In millions)

  43. Slide 43: Adjusted Operating Income

    Slide 43: Adjusted Operating Income

    Adjusted Operating Income ($ In Millions) 12 Months Ended December 31 12 Months Ended December 31 2004 2005 Product Sales $606 $731 Ribavirin Royalties 77 92 683 823 Cost of Goods Sold 200 223 Selling Expenses 193 229 General & Administrative 97 108 R&D 93 114 Amortization 55 61 Operating Income $45

  44. Slide 44: Adjusted Operating Income

    Slide 44: Adjusted Operating Income

    Adjusted Operating Income 2002 2003 2004 2005 Sales 209 139 45 88 Consolidated 2002 2003 2004 2005 Sales 2 43 79 127 ($ In millions) ($ In millions) Specialty Pharmaceuticals $139 $45 $88 $43 $79 $127 Note: Excludes R & D Division Note: Includes non-GAAP adjustments

  45. Slide 45: R&D Investment

    Slide 45: R&D Investment

    R & D Investment 2002 2003 2004 2005 Sales 50 45 93 114 ($ In millions) $45 $93 $114

  46. Slide 46: Solid Balance Sheet

    Slide 46: Solid Balance Sheet

    Solid Balance Sheet ($ In millions) December 2004 December 2005 Cash & marketable securities $462 $235 Other current assets $309 $361 Non-current assets $751 $935 Current liabilities $192 $235 Long-term debt $793 $788 Other liabilities $61 $69 Stockholders' Equity $476 $439 Includes assets and liabi

  47. Slide 47: Adjusted EBITDA

    Slide 47: Adjusted EBITDA

    Adjusted EBITDA 2002 2003 2004 2005 Specialty Pharma 53 97 140 200 2002 2003 2004 2005 Consolidated 263.1 204 127 177 Consolidated ($ In millions) ($ In millions) Specialty Pharmaceuticals $200 Note: Excludes R&D Division Includes non-GAAP adjustments

  48. Slide 48: Financial Metrics

    Slide 48: Financial Metrics

    2002A 2003A 2004A 2005A 2006E 2007E 2008E Cost of Goods Sold 11 8.7 15 16 2002A 2003A 2004A 2005A 2006E 2007E 2008E Cost of Goods Sold 35 32 32 31 2002A 2003A 2004A 2005A 2006E 2007E 2008E Cost of Goods Sold 34 35 33 31 2002A 2003A 2004A 2005A 2006E 2007E 2008E Cost of Goods Sold 27 21 16 15 Financi

  49. Slide 49: Financial Metrics

    Slide 49: Financial Metrics

    Financial Metrics 2003A (1) 2004A (1) 2005A (1) 2006E (1) (2) 2008E (2) (3) Cost of Goods Sold 36% 33% 31% 29-31% 20-25% Selling Expense 32% 32% 31% 29-31% 25-30% G & A 22% 16% 15% 11-13% 10-12% R&D 9% 15% 16% 15-17% 7-10% Effective Tax Rate 38% 26% 35% 29-31% 32-34% Includes non-GAAP adjustments wh

  50. Slide 50: Delivering Results, Keeping Our Promises

    Slide 50: Delivering Results, Keeping Our Promises

    Delivering Results Keeping Our Promises Positioning VRX for the Future

Source: SEC EDGAR · 8-K filed Apr 5, 2006

More decks from Valeant Pharmaceuticals International Inc